AN3025 / Adlai Nortye, Xiamen Biotime Biotech - LARVOL DELTA

Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity. (PubMed, Front Immunol) - "In addition, AN3025 in combination with anti-PD-1 antibody demonstrated stronger in-vivo anti-tumor activity. The potent anti-tumor efficacy of AN3025, either as a monotherapy or in combination with anti-PD-1 antibody, supports its further clinical development for the treatment of various human tumors."

IO biomarker • Journal • Immune Modulation • Inflammation • Oncology • CD4 • CD8 • IFNG • TNFRSF1B

Adlai Nortye Announces Publication of Preclinical Research of AN3025 (anti-hTNFR2) in Frontiers in Immunology (PRNewswire) - "Adlai Nortye Ltd...announced the publication of preclinical research of AN3025 (anti-hTNFR2）in the peer-reviewed journal Frontiers in Immunology...AN3025 treatment can reduce the proportion of regulatory T cells (Treg), increase the infiltration of effector CD4+ T cells and CD8+ T cells, and upregulate the expression of immune activation genes such as interferon-γ (IFN-γ) and granzyme K (Granzyme K) in the tumor microenvironment, leading to strong anti-tumor effects. AN3025 monotherapy significantly inhibits tumor growth both in PD-1-sensitive MC38 and in PD-1-resistant B16F10 animal tumor models. The combination of AN3025 and a PD-1 inhibitor shows superior anti-tumor effect than monotherapies preclinically...'AN3025 has shown great potentials for tumor control in preclinical studies, and we are very much looking forward to the clinical development of AN3025'."

Preclinical • Oncology

Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025) (PRNewswire) - "Adlai Nortye...announced that it has entered into a Global License Agreement with Xiamen Biotime Biotechnology Co., Ltd. ('Biotime') for several compounds. This includes the rights and interests of Adlai Nortye in the development, manufacturing and commercialization of AN4005 and AN3025 in Greater China, and AN1005, AN6015 and AN9015 worldwide. According to the terms of the agreement, the total amount of this cooperation will reach hundreds of millions of yuan, including the upfront payments, progress-dependent milestone payments and tiered royalties on sales."

Licensing / partnership • Oncology

[VIRTUAL] AN3025: A novel anti-human TNFR2 antibody that exhibits immune activation and strong anti-tumor activity in vivo (AACR 2021) - "AN3025 is a novel anti-hTNFR2 antibody and demonstrates immunomodulatory activity and potent anti-tumor efficacy in vivo, supporting its clinical development for the treatment of human cancers."

Preclinical • Oncology • IFNG • TNFRSF1B